School of Medicine
Showing 1-10 of 40 Results
-
Ewa Bielczyk Maczynska
Postdoctoral Scholar, Cardiovascular Medicine
Current Research and Scholarly Interestsregulation of adipocyte differentiation, fibrosis, TGF-beta signaling
-
Brototo Deb (Brodie)
Postdoctoral Scholar, Cardiovascular Medicine
BioWorking in the Computational Arrhythmia Lab, I am interested in using machine-learning-based analytical approaches to gain novel, interpretable insights into the pathophysiological mechanisms of arrhythmias and translate that into clinical practice. In my leisure, I like writing and reading poems, listening and (trying to) sing Indian classical music, apart from being an avid runner.
-
Prasanth Ganesan
Postdoctoral Scholar, Cardiovascular Medicine
Current Research and Scholarly InterestsSignal processing, Pattern recognition, Atrial fibrillation, Arrhythmia Mapping
-
Rodrigo Guarischi Sousa
Postdoctoral Scholar, Cardiovascular Medicine
Current Research and Scholarly InterestsAbsolutely passionate about bioinformatics and biological questions that can be addressed by DNA sequencing, especially ideas that may be applied to improve general public health.
-
Gentaro Ikeda
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
